Capital International Investors lowered its position in Johnson & Johnson (NYSE:JNJ) by 25.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,722,277 shares of the company’s stock after selling 4,898,022 shares during the quarter. Capital International Investors owned 0.56% of Johnson & Johnson worth $2,147,538,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Kessler Investment Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $29,000. Exchange Traded Concepts LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $31,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $31,000. NWK Group Inc. acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $61,000. Finally, Clear Investment Research LLC lifted its position in Johnson & Johnson by 23.1% in the fourth quarter. Clear Investment Research LLC now owns 539 shares of the company’s stock worth $79,000 after purchasing an additional 101 shares during the period. Hedge funds and other institutional investors own 69.30% of the company’s stock.
Shares of NYSE JNJ traded up $5.37 during mid-day trading on Thursday, reaching $124.77. The company had a trading volume of 5,327,248 shares, compared to its average volume of 15,986,437. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $154.50. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $314.20 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 1.99 and a beta of 0.74. The stock’s 50 day moving average is $140.69 and its 200-day moving average is $138.34.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.27%. The firm had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. During the same period in the prior year, the business posted $1.97 earnings per share. The business’s quarterly revenue was up 1.7% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.03 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 3.05%. The ex-dividend date of this dividend was Monday, February 24th. Johnson & Johnson’s payout ratio is 43.78%.
In other Johnson & Johnson news, Director William D. Perez bought 500 shares of the stock in a transaction on Friday, March 13th. The stock was purchased at an average price of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael E. Sneed sold 58,128 shares of Johnson & Johnson stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the sale, the chief operating officer now directly owns 107,511 shares of the company’s stock, valued at approximately $16,061,068.29. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
A number of equities research analysts have recently commented on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective for the company in a research report on Wednesday, December 18th. Credit Suisse Group cut their target price on shares of Johnson & Johnson from $170.00 to $159.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Wells Fargo & Co boosted their target price on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $145.00 to $170.00 in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $168.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $162.33.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.